BSEAsarfi Hospital LtdMinimalNeutral
Announced Tue, 12 May · 13:44 IST

We herewith a press release titled Extract of Audited Standalone and Consolidated financial Results of the Quarter and Year Ended March''31,2026 for your kind information and record.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-21.5%1-day move
₹248.50
prior close
₹202.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.5-0.0-1.2-1.2-21.5-24.3-21.5-21.7-22.3-20.8-15.1-7.8-13.1
Up moveDown movePending
AI summary

Asarfi Hospital Limited reported strong FY26 results with revenue growing 42% YoY to ₹117.3 Crore. The company achieved an EBITDA margin of 20% and PAT margin of 10%, driven by improved ARPOB, better realizations and enhanced case mix. Operational performance showed robust momentum with IPD revenue growing 45% YoY and OPD revenue increasing 14% YoY. The growth was supported by high-acuity specialties like Cardiology, Neurosciences and Orthopaedics, along with improved traction in Radiation Oncology at the cancer unit. The audited results were reviewed by the Audit Committee and approved by the Board of Directors on May 11, 2026.

Likely market impact

The 42% revenue growth and stable 10% PAT margin indicate strong operational leverage and execution capability, which should be viewed positively by investors. The growth in high-acuity specialties and ARPOB suggests improving quality of earnings and hospital bed utilization.